Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
SSRIs and SNRIs are prescribed as first-line pharmacological treatment for common mental disorders in children and adolescents. Despite their efficacy, they have a high risk for adverse events and exhibit a substantial placebo response. This editorial provides some background on the current evidence on the topic and suggests to carefully weigh the benefits of SSRIs and SNRIs against their potential harms. Therefore, the authors present two different set of conclusions - one for clinical practice, and one for future research designs.
